NASDAQ:FCSC

Fibrocell Science (FCSC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.00
$3.00
50-Day Range
$3.00
$3.00
52-Week Range
$1.45
$3.28
Volume
N/A
Average Volume
78,673 shs
Market Capitalization
$29.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FCSC stock logo

About Fibrocell Science Stock (NASDAQ:FCSC)

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

FCSC Stock News Headlines

Best Data Science Bootcamps Online In 2024
Science & Tech News
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Oramed Pharmaceuticals
See More Headlines
Receive FCSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FCSC
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-10,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$29.28 million
Optionable
Optionable
Beta
1.67
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. John Michael Maslowski (Age 44)
    Pres, CEO & Director
  • Mr. Sean D. Buckley (Age 37)
    VP of Bus. Admin. & Corp. Sec.
  • Mr. Robert G. Partridge
    VP of Global Marketing, Communications and Investor Relations
  • Ms. Michele Mchugh-Mazzatta
    VP of Sales
  • Dr. Pierre Compte
    Managing Director of Switzerland

FCSC Stock Analysis - Frequently Asked Questions

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) posted its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $1.30. The firm earned $21.79 million during the quarter.

When did Fibrocell Science's stock split?

Shares of Fibrocell Science reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Fibrocell Science own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Neurotrope (NTRP), Verastem (VSTM), Synergy Pharmaceuticals (SGYP) and Agile Therapeutics (AGRX).

This page (NASDAQ:FCSC) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners